NasdaqGM:HROWPharmaceuticals
A Fresh Look at Harrow (HROW) Valuation Following Strong Q3 Earnings and Growth Initiatives
Harrow (HROW) just released its third quarter earnings, catching the eye of investors with both impressive revenue growth and a shift from last year’s net loss to positive net income. The company’s results were supported by strong product performance and ongoing commercial expansion initiatives.
See our latest analysis for Harrow.
Harrow’s latest results come on the heels of significant commercial progress, yet the recent share price return shows a more cautious market mood, with a 1-year...